Drug Trial Radar · NCT07688577
XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Oct 21, 2026
Primary completion
Nov 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- Xilio Development, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.
Conditions
- Metastatic NSCLC - Non-Small Cell Lung Cancer
- Advanced Solid Tumor
Interventions
XTX501Drug
XTX501 monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLTs) in Part 1ATime frame: Cycle 1 Day 1 up to just prior to the second dose of study drug (approximately 21 days)
- Incidence of treatment-emergent adverse events (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
- Incidence of serious adverse events (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
- Incidence of significant change from baseline in clinical laboratory values (Phase 1 and Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
- Investigator-assessed objective response rate (ORR) per RECIST v1.1 (Phase 2)Time frame: Up to Safety Follow Up Period (90 [+7] days after the last dose)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site
Canton, Ohio · Recruiting
Investigator Site
Fort Worth, Texas · Recruiting
Investigator Site
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.